Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Short term Debt (2021 - 2024)

Standard Biotools (LAB) has disclosed Short term Debt for 6 consecutive years, with $54.9 million as the latest value for Q3 2024.

  • On a quarterly basis, Short term Debt rose 998.26% to $54.9 million in Q3 2024 year-over-year; TTM through Sep 2024 was $54.9 million, a 998.26% increase, with the full-year FY2023 number at $54.5 million, changed N/A from a year prior.
  • Short term Debt was $54.9 million for Q3 2024 at Standard Biotools, roughly flat from $54.7 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $54.9 million in Q3 2024 to a low of $833000.0 in Q3 2022.
  • A 3-year average of $25.4 million and a median of $5.0 million in 2023 define the central range for Short term Debt.
  • Peak YoY movement for Short term Debt: skyrocketed 500.24% in 2023, then soared 1539.84% in 2024.
  • Standard Biotools' Short term Debt stood at $833000.0 in 2022, then soared by 6446.22% to $54.5 million in 2023, then grew by 0.7% to $54.9 million in 2024.
  • Per Business Quant, the three most recent readings for LAB's Short term Debt are $54.9 million (Q3 2024), $54.7 million (Q1 2024), and $54.5 million (Q4 2023).